G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
Marilyn L. Slovak,Victoria Bedell,Danika Lew,Kathy S. Albain,Georgiana K. Ellis,Robert B. Livingston,Silvana Martino,Edith A. Perez,Gabriel N. Hortobagyi,Dorie Sher,Wendy Stock +10 more
TL;DR: A pilot clonality investigation to estimate the incidence of clonal hematopoiesis during and shortly after completion of the dose-intensive neoadjuvant regimens for high-risk breast cancer patients indicates that clonalHematopOiesis assays performed within the 2 years following dose- intensive neoadedjuvant therapy failed to identify an emerging clonal Hematoposietic stem cell population.
Journal Article
p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma
Jeffrey M. Resnick,Nour Sneige,Bonnie L. Kemp,Aysegul Sahin,Nelson G. Ordóñez,Debra Frye,Gabriel N. Hortobagyi +6 more
TL;DR: It is suggested that nuclear grade and immunoreactivity for c-erbB-2 may better predict response to preoperative chemotherapy than p53 expression.
Journal ArticleDOI
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation
Julius K. Weng,Xiudong Lei,Pamela J. Schlembach,Elizabeth S. Bloom,Simona F. Shaitelman,Isidora Arzu,Gregory M. Chronowski,Tomas Dvorak,Emily Grade,Karen E. Hoffman,George H. Perkins,Valerie Klairisa Reed,Shalin J. Shah,Michael C. Stauder,Eric A. Strom,Welela Tereffe,Wendy A. Woodward,Gabriel N. Hortobagyi,Kelly K. Hunt,Thomas A. Buchholz,Benjamin Smith +20 more
TL;DR: In this article, a randomized trial comparing conventional fractionated (CF) versus hypofractionated (HF) whole-breast irradiation (WBI) plus a boost was conducted.
Journal ArticleDOI
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: The M.D. Anderson Cancer Center experience
Massimo Cristofanilli,Frankie A. Holmes,Laura Esparza,Vicente Valero,Aman U. Buzdar,James Neidhart,Gabriel N. Hortobagyi,Gabriel N. Hortobagyi +7 more
TL;DR: It is concluded that high‐dose mitoxantrone therapy for metastatic breast cancer was relatively well tolerated but was not associated with a higher response rate than that of standard dose mitoxanrone.
Journal ArticleDOI
Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells
Kazuharu Kai,Takayuki Iwamoto,Takashi Kobayashi,Yoshimi Arima,Yayoi Takamoto,Nobuyuki Ohnishi,Chandra Bartholomeusz,Rie Horii,Futoshi Akiyama,Gabriel N. Hortobagyi,Lajos Pusztai,Hideyuki Saya,Naoto T. Ueno +12 more
TL;DR: Gene expression analysis revealed that CD49f− quiescent cells overexpressed epithelial-to-mesenchymal transition-driving genes, reminiscent of tumor-initiating cells and claudin-low breast cancer.